LMNX - Positive data on Pfizer/BioNTech COVID-19 vaccine pressures test makers

The sellers of diagnostic tests for SARS-CoV-2 and antibodies to the coronavirus are under early pressure in apparent reaction to positive interim data on Pfizer and BioNTech's COVID-19 vaccine that showed 90% efficacy. An effective vaccine, when widely deployed, will imply reduced testing demand.Selected tickers: Quidel ([[QDEL]] -30.1%), Hologic ([[HOLX]] -9.1%), Fluidigm ([[FLDM]] -22.8%), Abbott ([[ABT]] -4.5%), Roche ([[RHHBY]] -0.25%), Danaher ([[DHR]] -1.4%), OraSure Technologies ([[OSUR]] -14.3%), Luminex ([[LMNX]] -4.1%), Chembio Diagnostics ([[CEMI]] -7.2%), LabCorp ([[LH]] -6.4%), Quest Diagnostics ([[DGX]] -3.5%), Qiagen ([[QGEN]] -10.1%)

For further details see:

Positive data on Pfizer/BioNTech COVID-19 vaccine pressures test makers